SLC16A3 and neoplasm: Notably, MCT4 inhibition with VB124 activates the ROS/NF-κB signaling pathway, leading to increased expression of CXCL9 and CXCL10, which promotes CD8+ T cell infiltration into the tumor microenvironment.